MARC details
| 000 -LIDER |
|---|
| fixed length control field |
06592nam a22006015i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-3-031-28012-2 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240207153626.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
230628s2023 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783031280122 |
| -- |
978-3-031-28012-2 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
QH438.4.B55 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
R853.B54 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MBGR |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED000000 |
| Source |
bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MBGR |
| Source |
thema |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
610.72 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19 |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Paul C. Guest. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. 2023. |
| 264 #1 - |
|---|
| -- |
Cham : |
| -- |
Springer International Publishing : |
| -- |
Imprint: Springer, |
| -- |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XI, 513 p. 87 illus., 74 illus. in color. |
| Other physical details |
online resource. |
| 336 ## - |
|---|
| -- |
text |
| -- |
txt |
| -- |
rdacontent |
| 337 ## - |
|---|
| -- |
computer |
| -- |
c |
| -- |
rdamedia |
| 338 ## - |
|---|
| -- |
online resource |
| -- |
cr |
| -- |
rdacarrier |
| 347 ## - |
|---|
| -- |
text file |
| -- |
PDF |
| -- |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Proteomics, Metabolomics, Interactomics and Systems Biology, |
| International Standard Serial Number |
2730-6224 ; |
| Volume/sequential designation |
1412 |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Acceso multiusuario |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Chapter 1. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology and Variants of Concern -- Chapter 2. Long-term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics -- Chapter 3. Consequences of the Lockdown - Domestic Violence during the COVID-19 Pandemic -- Chapter 4. Psychological distress impact of Coronavirus disease (COVID-19) outbreak on three continents: A systematic review and meta-analysis -- Chapter 5. A Molecular Biomarker-based Triage Approach for Targeted Treatment of Post-COVID-19 Syndrome Patients with Persistent Neurological or Neuropsychiatric Symptoms -- Chapter 6. Genetic Associations with Coronavirus Susceptibility and Disease Severity -- Chapter 7. COVID Diagnostics: from Molecules to Omics -- Chapter 8. Assessing Biomarkers in Viral Infection -- Chapter 9. Proteomic Investigation of COVID-19 Severity During the Tsunamis Second Wave in Mumbai -- Chapter 10. NMR-Metabolomics in COVID-19 Research -- Chapter 11. Potential Biomarkers of Mitochondrial Dysfunction Associated with COVID-19 Infection -- Chapter 12. Red Cell Distribution Width as a Prognostic Indicator for Mortality and ICU Admission in Patients with COVID-19 -- Chapter 13. Predicting the COVID-19 Patients Status using Chest CT Scan Findings: A Risk Assessment Model Based on Decision Tree Analysis -- Chapter 14. Inferring Recombination Events in SARS-CoV-2 Variants In Silico -- Chapter 15. Amplicon-based Nanopore Sequencing of Patients Infected by the SARS-CoV-2 Omicron (B.1.1.529) Variant in India -- Chapter 16. Perspectives on Rapid Antigen Tests for Downstream Validation and Development of Theranostics -- Chapter 17. Machine Learning and COVID-19: Lessons from SARS-CoV-2 -- Chapter 18. The Relationship between Psoriasis, COVID-19 Infection and Vaccination during Treatment of Patients -- Chapter 19. Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV; Sinopharm) and Short-term Clinical Outcomes in Vaccinated Solid Organ Transplant Recipients: A Prospective Cohort Study -- Chapter 20. Spices and Biomarkers of COVID-19: A Mechanistic and Therapeutic Perspective -- Chapter 21. Antiviral Mechanisms of Curcumin and its Derivatives in Prevention and Treatment of COVID-19: A review -- Chapter 22. Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial -- Chapter 23. Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach -- Chapter 24. The Potential Effect of Royal Jelly on Biomarkers Related to COVID-19 Infection and Severe Progression -- Chapter 25. Statins: Beneficial Effects in Treatment of COVID-19 -- Chapter 26. Multiplex Immunoassay Approaches Using Luminex® xMAP® Technology for the Study of COVID-19 Disease -- Chapter 27. Rapid Detection of SARS-CoV-2 Variants of Concern by Genomic Surveillance Techniques. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics. This new volume reviews the most effective omic techniques for increasing our understanding of COVID-19, to improve diagnostics, prognostics, and genomic surveillance, and to facilitate development of effective treatments and vaccines. Chapters are written by an international team of experts and explore methods in the areas of genomics, transcriptomics, proteomics, and metabolomics. Techniques used to assess physiological function at the molecular level and artificial intelligence approaches used for more effective validation and translation of biomarker candidates into clinical use are also discussed. This book is an excellent resource for researchers studying biomarkers, virology, metabolic diseases, and infectious diseases, as well as clinical scientists, physicians, drug company scientists, and healthcare workers. |
| 541 ## - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Owner |
UABC ; |
| Method of acquisition |
Perpetuidad |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Biochemical markers. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Proteins. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Metabolism. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Genomics. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Biomarkers. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Proteins. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Metabolism. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Genomics. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Guest, Paul C. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer Nature eBook |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783031280115 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783031280139 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783031280146 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Proteomics, Metabolomics, Interactomics and Systems Biology, |
| -- |
2730-6224 ; |
| Volume number/sequential designation |
1412 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Public note |
Libro electrónico |
| Uniform Resource Identifier |
http://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-28012-2 |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 912 ## - |
|---|
| -- |
ZDB-2-SXB |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Libro Electrónico |
